Tested in a global trial, the drug regulates bone development and boosts growth rates in children with achondroplasia — the most common type of dwarfism.
Mironid has developed a compound to treat autosomal dominant polycystic kidney disease — a hereditary, progressive disease that affects around 12 million people worldwide.
The blood pressure drug nilvadipine increases blood flow to the brain's memory and learning centre among people with Alzheimer's disease without affecting other parts of the brain.
A trial into the treatment of chronic lymphocytic leukaemia has been so successful that the US FDA approved the treatment for patients with the disease prior to the trial data being presented.
Australian Pharmaceutical Manufacturers has opened expanded operations in the suburb of Keysborough, allowing the company to increase exports and create 44 new local jobs.
Scientists have added a 'homing beacon' to tumours, in the form of an injectable hydrogel, that attracts chemotherapy medicines towards cancer cells while sparing their normal counterparts.
In a large-scale, international study, 12.5 to 20% of patients who were given the drug on a daily basis experienced so-called sustained remission — a state that is almost like being cured.
Vaccitech has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100) to the first participants in a Flu 010 study.
MGC Pharmaceuticals has been granted a cannabis research licence in tandem with RMIT University, while Medlab Clinical has executed a heads of agreement for the further global distribution of its CBD/THC blend.
Researchers synthesised a family of molecules that are able to specifically bind a protein found in the cell membrane of more than 90% of neuroblastoma cells.
Pure stem cells provide a more effective treatment for osteoarthritis than traditional therapies, such as pain relief drugs, anti-inflammatories, prescribed exercise and knee surgery.
Scientists can use a 3D tumour structure to test several drugs or their combinations at different stages of the tumour's development.
Scientists have developed a single vaccination approach to simultaneously combat influenza and pneumococcal infections, while enhancing protection against both.
Researchers have been working to develop and optimise suitable bioinks for additive manufacturing, in the hope that we will soon be using 3D-printed biologically functional tissue to replace irreparably damaged tissue in the body.
Monash University has granted an exclusive licence of its portfolio of proprietary synthetic polymyxin antibiotics to Qpex Biopharma.